Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: February 14, 2019

Appendix 3B Amendment

Financial Reports 2019, News & Announcements 2019By Richard Mollard February 14, 2019

190214_Appendix 3B Amendment

Recent Articles

31 January 2020, Top 20 Shareholders
January 31, 2020
28 January, Appendix 4C and Quarterly Update
January 28, 2020
$700K R&D Tax Incentive Refund.
January 14, 2020
Epichem Awarded DNDi Contract Extension
January 8, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. ASX: $PAA

Retweet on Twitter PharmAust Retweeted

Epichem @epichem·

A pleasure to be guest speaker! Congratulations to the organisers. Fantastic to see a large cohort of students attend and take the opportunity to speak to potential employers, entrepreneurs and innovators in the Lifescience space. @MTPConnect_AUS @ribitdotnet @CityofPerth https://twitter.com/k8jbrooks/status/1232933348974026753

Dr Kate Brooks@k8jbrooks

And we are go on the first CSIRO @Data61news Ribit job networking event in Perth with support from @CityofPerth Thanks to our guest speaker @ColinLaGalia of @Epichem @MTPConnect_AUS @NewIndustriesWA @uwanews

Reply on Twitter 1233183896331681792 Retweet on Twitter 12331838963316817921 Like on Twitter 12331838963316817922 Twitter 1233183896331681792

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions